 |
VasoMedical to Showcase EECP® Therapy at Hospitalar 2013 in São Paulo, Brazil |
May 13, 2013 - WESTBURY, N.Y. - VasoMedical, Inc. (“VasoMedical”) (OTC BB:VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the Company will attend and exhibit at Hospitalar 2013, May 21 – May 24, 2013 in São Paulo, Brazil.
Hospitalar 2013 is the 20thInternational Fair of Products, Equipment, Services and Technology for Hospitals, Laboratories, Pharmacies, Health Clinics and Medical Offices. This São Paulo based annual event, the largest medical device show in South America and one of the largest in the world, attracts more than 1,250 exhibitors and, this year, expects 92,000 visitors from over 60 countries. At this event, VasoMedical will display and demonstrate its core technology, EECP® Therapy, its BIOX ambulatory monitoring products, and its EZ series patient management products.
“With the significant attendance of medical industry distributors, sales agents and representatives at Hospitalar, our focus at this event will be to increase awareness in the Latin American market about our company's offerings and the positive impact they can have on patients' lives,” said Larry Liebman, vice president, sales & marketing for VasoMedical. “Hospitalar is also a great opportunity for us to showcase our cost effective therapeutic and diagnostic products to many healthcare government officials, adminsitrative and medical personnel attending the four-day event,” Mr. Liebman continued. “By showcasing EECP® Therapy at Hospitalar, our goal is to promote EECP® Therapy as an effective, non-invasive treatment so that more physicians and other healthcare professionals in Latin America will turn to this Therapy as the go-to treatment option for patients suffering from heart diseases such as angina and heart failure.”
The VasoMedical - BIOX exhibit stand will be located at Booth 48 at the intersection of aisles O and M, in the Green Hall at Expo Center Norte Exhibition Center.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com
About BIOX Instruments
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, BIOX continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at http://www.biox.com.cn/bioxen/default.asp.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com